U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6337761

Indenolol hydrochloride is a mixture of 1-(7-in-denyloxy)-3-isopropylamino-2-propanol monohydrochloride and 1-(4-indenyloxy)-3-isopr opylamino-2-propanol monohydrochloride. Indenolol is a non-cardioselective beta blocker used to treat hypertension.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Blocker
537
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
PULSAN

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Synthesis of new indene derivatives with -adrenergic blocking properties].
1972 Nov
Indenolol in hypertension.
1983 Mar
Indenolol: a new antihypertensive agent: efficacy, toxicity, and hemodynamic effects in a crossover double-blind study with metoprolol.
1985 Jul-Aug
Patents

Patents

BE 641417
1
DE 1955229
1

Sample Use Guides

In Vivo Use Guide
In clinical trials against hypertension, indenolol was administered daily at doses of 60 mg or 120 mg.
Route of Administration: Oral
In Vitro Use Guide
Indenolol hydrochloride exhibited beta-blocking activity in isolated atria with pA2 of 8.38.
Substance Class Mixture
Created
by admin
on Fri Dec 15 17:36:55 GMT 2023
Edited
by admin
on Fri Dec 15 17:36:55 GMT 2023
Record UNII
2VLW0IV0ZQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INDENOLOL HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
INDENOLOL HYDROCHLORIDE [JAN]
Common Name English
INDENOLOL HYDROCHLORIDE [MART.]
Common Name English
INDENOLOL HYDROCHLORIDE [MI]
Common Name English
INDENOLOL HCL
Common Name English
Indenolol hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
CAS
81789-85-7
Created by admin on Fri Dec 15 17:36:55 GMT 2023 , Edited by admin on Fri Dec 15 17:36:55 GMT 2023
PRIMARY
EPA CompTox
DTXSID00988612
Created by admin on Fri Dec 15 17:36:55 GMT 2023 , Edited by admin on Fri Dec 15 17:36:55 GMT 2023
PRIMARY
FDA UNII
2VLW0IV0ZQ
Created by admin on Fri Dec 15 17:36:55 GMT 2023 , Edited by admin on Fri Dec 15 17:36:55 GMT 2023
PRIMARY
EVMPD
SUB02664MIG
Created by admin on Fri Dec 15 17:36:55 GMT 2023 , Edited by admin on Fri Dec 15 17:36:55 GMT 2023
PRIMARY
CAS
68906-88-7
Created by admin on Fri Dec 15 17:36:55 GMT 2023 , Edited by admin on Fri Dec 15 17:36:55 GMT 2023
SUPERSEDED
ChEMBL
CHEMBL153585
Created by admin on Fri Dec 15 17:36:55 GMT 2023 , Edited by admin on Fri Dec 15 17:36:55 GMT 2023
PRIMARY
MERCK INDEX
m6249
Created by admin on Fri Dec 15 17:36:55 GMT 2023 , Edited by admin on Fri Dec 15 17:36:55 GMT 2023
PRIMARY Merck Index
SMS_ID
100000086963
Created by admin on Fri Dec 15 17:36:55 GMT 2023 , Edited by admin on Fri Dec 15 17:36:55 GMT 2023
PRIMARY
All of the following components must be present:
Structure of 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDENE HYDROCHLORIDE
Structure of 7-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDENE HYDROCHLORIDE
Definition References
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966